Document:

EXHIBIT 4.1

                         VOID AFTER  _______________

                           PRIMECARE SYSTEMS, INC.

                               Non-Transferable

                                           Right to Purchase __________ Shares
                                                       (Subject to adjustment)

                  Stock Purchase Warrant for Common Stock of
                           PrimeCare Systems, Inc.

THE WARRANTS REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER
THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), AND MAY NOT BE OFFERED,
SOLD OR OTHERWISE TRANSFERRED WITHOUT REGISTRATION OR UNLESS PURSUANT TO AN
EXEMPTION FROM REGISTRATION UNDER THE ACT, THE AVAILABILITY OF WHICH IS TO
BE ESTABLISHED TO THE SATISFACTION OF THE CORPORATION AS HEREIN SET FORTH.

   PrmeCare Systems, Inc. (hereinafter called the "Company"), a Delaware
Corporation, hereby certifies that, for value received,
______________________________ is entitled to purchase from the Company, at
any time or from time to time prior to 3:00 PM, New York City local time, on
____________, an aggregate of ______________ fully paid and nonassessable
shares (the number and character of such shares being subject to adjustment
as provided below") of the Common Stock, $.001 par value, of the Company
(the "Common Stock"), on the payment therefore of the purchase price which
shall be equal to $________ per share of the Common Stock, until this
Warrant expires as provided herein, for each share of the Common Stock
subscribed for and purchased, upon the surrender of this Warrant duly signed
by the registered holder hereof, accompanied by payment of the purchase
price, upon the terms and subject to the conditions hereinafter set forth.

  EXERCISE OF WARRANT.  The  holder shall surrender this Warrant to the
principal office of the Company, with the exercise form on the last page of
this Warrant duly signed together with the purchase price of the Common
Stock (as well as any applicable transfer taxes if the Common Stock is to be
registered in any name other than that of the registered holder hereof)
represented by certified or official bank check payable to the order of the
Company.

  DELIVERY OF STOCK CERTIFICATE ON EXERCISE.  As soon as practicable after
the exercise of this Warrant and payment of the purchase price, the Company
will cause to be issued in the name of and delivered to the registered
holder hereof, or such holder's nominee, a certificate or certificates for
the number of full shares of the Common Stock of the Company to which such
holder shall be entitled upon such exercise, together with, in the case of a
partial exercise of this Warrant, a new Warrant certificate of like tenor
herewith representing the right to purchase the balance of shares subject
hereto after giving effect to such partial exercise.  In case, between the
date of any exercise hereof and the date on which the certificate or
certificates are issued, the record holders of shares of Common Stock of the
Company shall become entitled to any dividend or other right, the Company
will forthwith pay or cause to be paid in cash to the holder hereof the
amount of such dividend, or transfer to the holder thereof such right, as
the case may be.

  No fraction of a share or scrip certificate for such a fraction shall be
issued upon the exercise of this Warrant; in lieu thereof, the Company will
pay or cause to be paid to such holder cash equal to a like fraction at the
prevailing market price for such share as determined by the Company.

  ADJUSTMENTS TO BASIS FOR CONVERSION.  Whenever the Company shall (A)
declare a dividend on its Common Stock in shares of Common Stock, (B)
subdivide its outstanding Common Stock, (C) combine its outstanding shares
of Common Stock into a smaller number of shares, or  (D) issue any shares
upon reclassification of its Common Stock (including any such
reclassification in connection with a consolidation or merger in which the
Company is the surviving corporation, then and in each such case, the holder
of this Warrant, upon the exercise hereof and upon the payment of the sum
obtained by multiplying (1) the number of shares of the Common Stock of the
Company as to which this Warrant is then being so exercised by (2) the
purchase price per share stated on the face of this warrant, as well as any
applicable transfer taxes, shall be entitled to receive, in lieu of the
shares called for hereby, the stock or other securities or property, which
said holder would hold on the date of such exercise, if, from the date
hereof to and including such date, he had been the holder of record of the
number of shares of the Common Stock of the Company as to which this Warrant
is then being so exercised and had retained such shares and all such other
or additional or less stock and other securities and property receivable in
respect of such shares.

  REORGANIZATIONS,  CONSOLIDATIONS,  MERGERS.  In case of any reorganization
of the Company, or  any other corporation, the stock or securities of which
are at the time deliverable on the exercise of this Warrant, or in case the
Company or such other corporation shall consolidate with or merge into
another corporation, or convey all or substantially all of its assets to
another corporation, the holder of this Warrant, upon the exercise hereof
and upon the payment of the sum obtained by multiplying (a) the number of
shares of the Company as to which this Warrant is then being so exercised by
(b) the purchase price per share stated on the face of this Warrant, as well
as any applicable transfer taxes, shall be entitled to receive, in lieu of
the shares theretofore called for hereby, the stock or other securities or
property to which such holder hereof would have been entitled upon the
consummation of such reorganization, consolidation, merger or conveyance if
he had purchased the shares as to which this Warrant is then being so
exercised immediately prior thereto; and in such case, the provisions of
this Warrant shall be applicable to the shares of stock or other securities
or property thereafter deliverable upon the exercise of this Warrant.

  EXCHANGE OF  WARRANTS.  Upon the surrender by any registered holder of any
Warrant or Warrants at the principal office of the Company or of the
Transfer Agent for its Common Stock, the Company will issue and deliver to,
or on the order of, such holder, at the Company's expense, a new Warrant or
Warrants in the name of such holder (upon the payment by such holder of any
applicable transfer tax) may direct, in such authorized denomination or
denominations as such holder may request, evidencing the  right to purchase
an aggregate amount of stock or securities equal to the aggregate amount of
stock or securities which the Warrant or Warrants so surrendered evidenced
the right to purchase.

  LOST, STOLEN, DESTROYED OR MUTILATED WARRANTS.  Upon receipt by the
Company of evidence satisfactory to it of the ownership of and the loss,
theft or destruction or mutilation of any Warrants, (in the case of loss,
theft, or destruction) of indemnity satisfactory to it, and (in the case of
mutilation) upon the surrender and cancellation thereof, the Company will
issue and deliver, in lieu thereof, a new Warrant of like tenor.

  RESTRICTIONS OF TRANSFER.  This Warrant may not be transferred.  The
transfer of the shares of Common Stock which may be purchased upon the
exercise thereof is restricted and subject to the applicable provisions of
the Securities Act of 1933, as amended.  The shares of Common Stock which
may be purchased upon the exercise thereof may not be sold, transferred,
pledged or hypothecated in the absence of any effective registration
statement or post-effective amendment thereto for such shares of Common
Stock under such Act, or an opinion of counsel to the Company that
registration is not required under such Act.

  MISCELLANEOUS.  This Warrant does not confer upon the holder any rights of
a stockholder of the Company, including, without limitation, any right to
vote or to consent or to receive notice as a stockholder of the Company.

  EXPIRATION.  This Warrant will be wholly void and of no effect after 3:00
PM, New York City local time, on ________________ .

  LAW GOVERNING.  This Warrant shall be governed by, and construed and
enforced in accordance with, the laws of the State of Delaware, without
reference to any conflict of laws provision thereof.

  Dated: ___________                PRMECARE SYSTEMS, INC.

                                    Edward C. Levine,
                                    President

  Attest:

  Jeffrey P. Nelson,
  Secretary

                              SUBSCRIPTION FORM

 The undersigned irrevocably exercised this Warrant to the extent of shares
of Common Stock of PRIMECARE SYSTEMS, INC., called for hereby, and herewith
makes payment therefore, all at the price and on the terms and conditions
specified herein.

Number of Shares:__________________

Dated: ____________________________

Name:  ____________________________
      (signature)

 ____________________________
      (Please Print Name)

Social Security or Employer ID #__________________________

Address:  ________________________________________________

City & State:  ___________________________________________

Zip Code:  _________Exhibit  No.  10.1

================================================================================

                      AGREEMENT AND PLAN OF REORGANIZATION

                              by, between and among

                              OCG TECHNOLOGY, INC.

                       EPIDEMIC INTERVENTION SYSTEMS, INC.

                     CENTERSTAGING MUSICAL PRODUCTIONS, INC.

                                       and

                            OTHER SIGNATORIES HERETO

                           Dated as of March 15, 2005

================================================================================

                      AGREEMENT AND PLAN OF REORGANIZATION

      THIS AGREEMENT AND PLAN OF REORGANIZATION (this "Agreement"), dated as of
March 15, 2005, is made and entered into by and among OCG TECHNOLOGY, INC., a
Delaware corporation ("OCG"), EPIDEMIC INTERVENTION SYSTEMS, INC., a Delaware
corporation and direct, wholly-owned subsidiary of OCG ("Merger Sub"),
CENTERSTAGING MUSICAL PRODUCTIONS, INC., a California corporation ("CMPI"),
Johnny Caswell, Howard Livingston, Roger Paglia and Jan Parent (collectively,
the "CMPI Shareholders"), PrimeCare Systems, Inc., a Delaware corporation and
direct, wholly-owned subsidiary of OCG ("PSI"), and Edward Levine, the
President
and a stockholder of OCG ("Levine"), with reference to the following facts:

RECITALS:

      WHEREAS, after carrying out the transactions described in Section 1.1,
the
respective boards of directors of OCG, Merger Sub and CMPI deem it advisable
and
in the best interests of their respective stockholders that Merger Sub merge
with and into CMPI (the "Merger") upon the terms and subject to the conditions
set forth herein; and

      WHEREAS the respective boards of directors of OCG, Merger Sub and CMPI
have approved the Merger; and

      WHEREAS, as in inducement to the other parties to enter into this
Agreement and to consummate the Merger and the other transactions contemplated
herein, the parties hereto are willing to make certain representations and
warranties as set forth herein; and

      NOW, THEREFORE, in consideration of the premises and the representations,
warranties and agreements contained herein, the parties hereto agree as
follows:

ARTICLE I

PRE-CLOSING TRANSACTIONS AND THE MERGER

1.1   Spin-off of PSI

            (a) Prior to the Effective Time (as defined in Section 1.5), OCG
      shall (i) transfer, assign and contribute to PSI (1) all of OCG's shares
      of capital stock of its wholly-owned subsidiaries, Optronics Labs,
Inc., a
      New York corporation, and Mooney Edwards Enterprises, Inc., a Florida

      corporation, (2) all of OCG's operating assets, if any, but excluding the
      Excluded Assets (as hereinafter defined), and (3) all of OCG's
Liabilities
      (as hereinafter defined), and (ii) declare and pay with respect to the
OCG
      Common Stock and OCG Series C Stock (each as defined in Section 5.2)
      outstanding as of the record date therefor established by OCG (the
"Record
      Date") a dividend of all of the shares of capital stock of PSI held by
OCG
      in a spin-off transaction as provided in Section 8.10 (collectively, the
      "Spin-off").

            (b) "Excluded Assets" for purposes of this Section 1.1 means all
      stock books, minute books, tax returns and other books and records of
OCG.

            (c) "Liabilities" for purposes of this Agreement means any and all
      direct or indirect liabilities, indebtedness, obligations, commitments,
      claims, deficiencies, expenses, deferred income, guaranties or
      endorsements of any type, whether known, unknown, accrued, absolute,
      contingent, matured or unmatured.

            (d) In connection with the Spin-off, OCG shall use its best efforts
      to obtain from all or substantially all of its creditors written
      statements, in form and content satisfactory to CMPI, by which such
      creditors agree to PSI's assumption of all of OCG's Liabilities to such
      creditors pursuant to the Spin-off and to release and hold harmless OCG

      and the Surviving Corporation from and against such Liabilities following
      the Closing.

1.2   Exchange of Options

      Prior to the Effective Time, OCG shall cause PSI to offer, as of the
Record Date, to each holder on such date of options, warrants or other
rights to
subscribe for or purchase OCG Common Stock (collectively, the "OCG Stock
Rights"), in exchange therefor, an option, warrant or similar right to
subscribe

for or purchase an equivalent number of shares of stock of PSI on substantially
the same terms and conditions as those contained in such corresponding OCG
Stock
Rights (the "Exchange Offer"). The Exchange Offer shall occur as of, and shall
be conditioned upon, the Closing (as defined in Section 3.6).

1.3   Authorization of Series F Preferred Stock

      OCG has, or before the Closing will have, duly created a series of the
authorized shares of its preferred stock, designated Series F Preferred Stock
(the "OCG Series F Stock") and having the rights, restrictions, privileges and

preferences set forth in the form of Certificate of Designation Creating Series
F Preferred Stock (the "Certificate of Designations") attached as Exhibit A to
this Agreement. OCG also has, or before the Closing will have, duly authorized
the issuance and sale of shares of OCG Series F Stock pursuant to the Merger.

1.4   Advances by CMPI

      Prior to the date hereof, CMPI has advanced to OCG the principal sum of
$75,000, including $50,000 evidenced by that certain Promissory Note of OCG,

dated November 24, 2004 (the "Original Promissory Note"). Concurrently with the
execution of this Agreement, CMPI shall advance to OCG an additional $25,000,
and, following the date hereof, CMPI agrees to make further advances to OCG of
up to $75,000 in the aggregate upon request by OCG as follows and in the
following order of priority:

            (a) $25,000 upon the later to occur of (i) March 23, 2005 or (ii)
      OCG's filing with the Securities and Exchange Commission ("SEC") of a
      registration statement on Form SB-2 or other available form relating to
      the Spin-off contemplated in Section 1.1, above;

            (b) subject to the prior advance in subparagraph (a), above, an
      additional $25,000 upon the later to occur of (i) March 30, 2005 or (ii)
      OCG furnishing to CMPI the signed statements referred to in Section
1.1(d)
      of the holders of not less than 80% of the aggregate Liabilities of OCG
      (excluding for this purpose all Liabilities owed to telephone service
      providers and public utilities); and

                  (i) subject to the prior advances pursuant to subparagraph
(a)
            and (b), above, an additional $25,000 on April 6, 2005.

      Concurrently with the execution of this Agreement, OCG shall surrender to

CMPI for cancellation the Original Promissory Note in exchange for a promissory
note of OCG, in the form attached hereto as Exhibit B to this Agreement, which
promissory note shall evidence all of the foregoing sums advanced by CMPI (the
"New Promissory Note").

1.5   Additional Cash Requirements

      PSI and Levine agree, jointly and severally, that they shall pay or

provide to OCG any and all cash in excess of the amounts advanced by CMPI under

Section 1.4, above, as is necessary to enable OCG to meet its obligations under
this Agreement and other working capital and general corporate needs for the

period prior to the Closing. To the extent any such amounts are provided in the
form of an advance or loan to OCG, they shall be forgiven as of the Closing
without any further obligation or Liability on the part of OCG.

1.6   The Merger

      Upon the terms and subject to the conditions hereof, at the Effective
Time, Merger Sub shall merge with and into CMPI and the separate corporate
existence of Merger Sub shall thereupon cease, and CMPI shall be the surviving
corporation in the Merger (the "Surviving Corporation"). The Merger shall have
the effects set forth in this Agreement and in Chapter 11 of the California
General Corporation Law (the "CGCL") and Subchapter IX of the Delaware General
Corporation Law (the "DGCL").

                                       2

1.7   Effective Time of the Merger

      The Merger shall become effective at or following the Closing upon the

filing with the respective Secretaries of State of the States of California and
Delaware of an agreement of merger (the "Agreement of Merger") in accordance
with the requirements of the CGCL and the DGCL (the "Effective Time").

1.8   Tax Treatment

      It is intended that the Merger shall qualify as a reorganization under
Section 368(a)(2)(E) of the Internal Revenue Code of 1986, as amended (the
"Code"), and related sections and Treasury Regulations thereunder.

ARTICLE II

THE SURVIVING CORPORATION

2.1   Certificate of Incorporation

      The articles of incorporation of CMPI in effect immediately prior to the
Effective Time shall be the articles of incorporation of the Surviving
Corporation at and after the Effective Time, and thereafter may be amended in
accordance with the terms thereof and the CGCL.

2.2   Bylaws

      The bylaws of CMPI in effect immediately prior to the Effective Time
shall

be the bylaws of the Surviving Corporation at and after the Effective Time, and

thereafter may be amended in accordance with their terms and as provided by the
articles of incorporation of the Surviving Corporation and the CGCL.

2.3   Directors and Officers

      At and after the Effective Time, the directors and officers of the
Surviving Corporation shall be the directors and officers of CMPI immediately
prior to the Effective Time, until their respective successors have been duly

elected or appointed and qualified or until their earlier death, resignation or
removal in accordance with the articles of incorporation and bylaws of the
Surviving Corporation.

ARTICLE III

CONVERSION OF SHARES

3.1   Conversion of Capital Stock

      As of the Effective Time, by virtue of the Merger and without any action
on the part of the holders of any capital stock or other securities described
below:

            (a) Each share of the common stock, no par value per share, of CMPI
      ("CMPI Common Stock") issued and outstanding immediately prior to the
      Effective Time shall be converted into and exchanged for the right to
      receive fully paid and nonassessable shares of OCG Series F Stock as
      provided herein. All such CMPI Common Stock, when so converted and
      exchanged, shall no longer be outstanding and shall automatically be
      canceled and retired, and the holder of a certificate ("CMPI Stock
      Certificate") that, immediately prior to the Effective Time, represented
      outstanding shares of CMPI Common Stock shall cease to have any rights
      with respect thereto, except the right to receive, upon the surrender of
      such CMPI Stock Certificate, the shares of OCG Series F Stock (the
"Merger
      Shares") to which such holder is entitled pursuant to this Section
3.1(a).
      Until surrendered as contemplated by this Section 3.1(a) and Section

      3.3(a), each CMPI Stock Certificate shall be deemed at any time after the

      Effective Time to represent only the right to receive upon such surrender
      the Merger Shares as contemplated by this Section 3.1(a). Subject to
      Section 3.1(c), below, the number of shares of OCG Series F Stock that
      will be issued as a result of the Merger for each share of CMPI Common
      Stock will equal the quotient determined by dividing (i) the number of

      shares of OCG Series F Stock determined by the formula [(X / .04) x .96)]

      / 10,000, where X equals the sum of (1) the total number of shares of OCG
      Common Stock outstanding as of the Effective Time plus (2) the total
      number of shares of OCG Common Stock issuable upon conversion, in
full, of
      all OCG Series C Stock (as defined in Section 5.2) outstanding as of the

                                       3

      Effective Time plus (3) the total number of shares of OCG Common Stock
      issuable upon the exercise, in full, of any and all shares of OCG Stock
      Rights outstanding as of the Effective Time by (ii) the total number of
      shares of CMPI Common Stock issued and outstanding immediately prior to
      the Effective Time. The number of shares of OCG Series F Stock to be so
      issued for each share of CMPI Common Stock is referred to herein as the
      "Exchange Ratio."

            (b) All outstanding convertible promissory notes of CMPI (the "CMPI
      Convertible Notes") outstanding immediately prior to the Effective Time
      shall be assumed by and become the principal liabilities and obligations
      of OCG on the same terms and conditions thereof as existed immediately
      prior to the Effective Date, which notes shall be convertible into such
      number of shares of OCG Common Stock (as defined in Section 5.2)
      determined in accordance with the terms of such notes. The "Retained

      Merger Shares" (as defined in Section 3.2(c)) otherwise to be received in
      the Merger by the CMPI Shareholders shall be subject to cancellation as
      provided in Section 9.1 based upon such future conversion of the CMPI
      Convertible Notes.

            (c) Notwithstanding the foregoing, if, between the date of this
      Agreement and the Effective Time, the outstanding shares of OCG Series F
      Stock or other class or series of OCG Capital Stock (as defined in
Section

      5.2) or CMPI Common Stock shall have been changed into a different number
      of shares or a different class, by reason of any stock dividend,
      subdivision, reclassification, recapitalization, split, combination or
      exchange of shares, the Exchange Ratio shall be correspondingly adjusted
      to reflect such stock dividend, subdivision, reclassification,
      recapitalization, split, combination or exchange of shares; and

            (d) Each share of the common stock, $.001 par value per share, of
      Merger Sub (the "Merger Sub Common Stock") issued and outstanding
      immediately prior to the Effective Time shall automatically be converted
      into the same number of shares of common stock of the Surviving
      Corporation, and shall, immediately after the Merger, be the only shares
      of capital stock of the Surviving Corporation issued and outstanding.

            (e) Each share of each class and series of OCG Capital Stock issued
      and outstanding immediately prior to the Effective Time shall remain
      outstanding and shall not be affected by the Merger.

            (f) All OCG Series F Stock issued upon the surrender of the CMPI

      Stock Certificates in accordance with the terms hereof shall be deemed to
      have been issued in full satisfaction of all rights pertaining to such
      CMPI Stock Certificates and the CMPI Common Stock formerly represented
      thereby; and from and after the Effective Time there shall be no further
      registration of transfers effected on the stock transfer books of the
      Surviving Corporation of shares of the CMPI Common Stock which were
      outstanding immediately prior to the Effective Time. If, after the
      Effective Time, CMPI Stock Certificates are presented to the Surviving
      Corporation for any reason, they shall be canceled and exchanged as
      provided in this Article III.

      (g) The parties agree that, notwithstanding any other provision of this
Agreement, the holders of the shares denominated as "X" in the equation set
forth in Section 3.1(a), above, shall own in the aggregate 4% of total
number of
shares of OCG Common Stock outstanding and issuable upon conversion of
outstanding OCG Series C Stock and any outstanding OCG Stock Rights as of the
Effective Time and after giving effect to the conversion, in full, of the CMPI

Convertible Notes following the Closing (but without giving effect to any other
transactions or events subsequent to the Closing).

3.2   Initial Merger Shares

      (a) For purposes of this Agreement the following terms shall have the
meanings indicated:

            (i) "Maximum CMPI Note Conversion Shares" shall mean the maximum
      possible number of shares of OCG Common Stock issuable upon the
      conversion, in full, of the CMPI Convertible Notes outstanding as of the
      Effective Time;

                                       4

                  (ii) "Actual CMPI Note Conversion Shares" shall mean the
            actual cumulative aggregate number of shares of CMPI Common Stock

            issued upon the conversion, in full, of the CMPI Convertible Notes;

                  (iii) "Series F Conversion Shares" shall mean the number of
            shares of OCG Common Stock issuable upon the conversion, in
full, of
            the aggregate Merger Shares issuable in the Merger to the CMPI
            Shareholders; and

                  (iv) "Retention Ratio" shall mean the ratio that the Maximum
            CMPI Note Conversion Shares bears to the Series F Conversion
Shares.

            (b) Notwithstanding any other provisions of this Agreement, the

      initial aggregate number of shares of OCG Series F Stock to be issued and
      delivered to the CMPI Shareholders at the Closing (the "Initial Merger
      Shares") shall be equal to the product of the total Merger Shares to
which
      they otherwise would be entitled under Section 3.1(a) multiplied by the
      Retention Ratio. The Initial Merger Shares shall be issuable and
      distributable at the Closing to the CMPI Shareholders pro rata in
      accordance with their ownership of CMPI Common Stock.

            (c) In addition to the Initial Merger Shares issuable pursuant to
      subparagraph (b), above, at the Closing the balance of the Merger Shares
      to which the CMPI Shareholders are entitled under Section 3.1(a) (the

      "Retained Merger Shares") shall be issued by OCG in the names of the CMPI
      Shareholders entitled thereto, and in such denominations to which such
      holders are entitled, pursuant to Section 3.1(a), but shall be
retained by
      OCG in escrow as provided in Article IX. Upon the future conversion or
      satisfaction and cancellation, as the case may be, of the CMPI
Convertible
      Notes, the Retained Merger Shares shall be cancelled by OCG or
released to

      the CMPI Shareholders, as the case may be, in accordance with Article IX.

3.3   Surrender and Payment

            (a) At the Closing, OCG shall issue and deliver to each holder
of a
      CMPI Stock Certificate that immediately prior to the Effective Time
      represented outstanding CMPI Common Stock, the Merger Shares or the
      Initial Merger Shares, as the case may be, to which such holder is

      entitled, in exchange for the holder's surrender for cancellation of such
      CMPI Stock Certificate.

            (b) If any shares of OCG Series F Stock are to be issued to a
Person
      (as hereinafter defined) other than the registered holder of the CMPI
      Stock Certificates surrendered in exchange therefor, it shall be a
      condition to such issuance that the CMPI Stock Certificates so
surrendered
      shall be properly endorsed or otherwise be in proper form for transfer
and

      that the Person requesting such issuance shall pay to OCG any transfer or
      other taxes required as a result of such issuance to a Person other than
      the registered holder or establish to the satisfaction of the OCG that
      such tax has been paid or is not applicable.

            (c) For purposes of this Agreement, "Person" means an
individual, a
      corporation, a limited-liability company, a partnership, an
association, a
      trust or any other entity or organization, including a governmental or
      political subdivision or any agency or instrumentality thereof.

            (d) If any CMPI Stock Certificate shall have been lost, stolen or
      destroyed, upon the making of an affidavit of that fact by the Person

      claiming such CMPI Stock Certificate to be lost, stolen or destroyed, OCG
      will issue in exchange for such lost, stolen or destroyed CMPI Stock
      Certificate the Merger Shares deliverable in respect thereof pursuant to
      this Agreement. OCG, in its discretion, may require as a condition to
such
      issuance that such Person also agree to indemnify, defend and hold

      harmless OCG from and against any Liability to any Person with respect to
      such lost, stolen or destroyed CMPI Stock Certificate.

                                       5

3.4   OCG Preferred Stock

      Prior to the Closing, OCG shall take such actions as are necessary to
retire the classes of OCG Control Stock designated "Series A Preferred Stock"
and "Series B Preferred Stock," respectively, so that neither such class of
shares shall be authorized as of the Closing.

3.5   No Fractional Shares
      [Intentionally Omitted.]

3.6   Closing

            (a) The closing of the transactions contemplated by this Agreement
      (the "Closing") shall take place at the offices of Troy & Gould
      Professional Corporation, 1801 Century Park East, Suite 1600, Los
Angeles,
      California, at 10:00 A.M., local time, on the third business day
following
      the first date as of which all of the conditions set forth in Article X
      hereof shall have been satisfied or waived, or at such other date and
time
      as OCG and CMPI shall otherwise agree in writing (either such date, (the
      "Closing Date").

            (b) At the Closing, (i) OCG and Merger Sub shall deliver the
various

      certificates, instruments, and documents referred to in subparagraph (c),
      below, (ii) CMPI shall deliver the various certificates, instruments and
      documents referred to in subparagraph (d), below, (iii) CMPI and Merger
      Sub shall execute and file the Agreement of Merger with the respective
      Secretaries of State of the States of California and Delaware, and (v)
the
      parties hereto shall make any payments and undertake any other actions
      provided for in this Section 3.6 in accordance with the terms of this
      Agreement.

            (c) At the Closing, OCG or Merger Sub, as applicable, shall deliver
      the following:

                        (i) OCG shall issue and deliver the Merger Shares and
                  issue and retain the Retained Merger Shares as provided in
                  Sections 3.2(a) and 3.3(a), respectively; and

                        (ii) OCG and Merger Sub shall furnish CMPI with:

                  (A) a certificate executed by the Secretary or an Assistant
            Secretary of each of OCG and Merger Sub certifying as of the
date of
            the Closing Date (1) a true and complete copy of the respective

            certificate of incorporation of OCG and Merger Sub, certified as of
            a recent date by the Secretary of State of the State of Delaware,
            and a true and complete copy of the respective bylaws of OCG and

            Merger Sub, as certified by the Secretary or an Assistant Secretary
            of OCG and Merger Sub, as applicable, and (2) a true and complete
            copy of the resolutions of the respective boards of directors of
OCG
            and Merger Sub authorizing the execution, delivery and performance

            of this Agreement by OCG and Merger Sub and the consummation of the
            transactions contemplated hereby; and

                  (B) a certificate of the Secretary of State of the State of

            Delaware certifying the good standing of OCG and Merger Sub in such
            State, in each case, dated within 10 days of the Closing Date.

      (d) At the Closing, CMPI shall furnish OCG and Merger Sub with:

                        (i) a certificate executed by the Secretary or an
                  Assistant Secretary of CMPI certifying as of the date of the
                  Closing Date (1) a true and complete copy of the articles of
                  incorporation of CMPI, certified as of a recent date by the

                  Secretary of State of the State of California, and a true and
                  complete copy of the bylaws of CMPI, certified by the
                  Secretary or an Assistant Secretary of CMPI, and (2) a true
                  and complete copy of the resolutions of the board of
directors
                  of CMPI authorizing the execution, delivery and
performance of
                  this Agreement and the consummation of the transactions
                  contemplated hereby; and

                                       6

                        (ii) a certificate of each appropriate Secretary of
                  State certifying the good standing of CMPI in California and
                  in all states in which it is qualified to do business, in
each
                  case, dated within 10 days of the Closing Date.

                  (e) At the Closing, CMPI shall pay and deliver to PSI, by
wire

            transfer to an account of PSI designated by PSI in writing prior to
            the Closing Date, an amount equal to the difference, if any,
between
            $200,000 and the cumulative amount theretofore advanced by CMPI to
            OCG as evidenced by the New Promissory Note referred to in Section
            1.4.

                  (f) At the Closing, OCG shall deliver to CMPI the signed
            statements of the former creditors of OCG referred to in Section
            1.1(d).

                  (g) At the Closing, OCG shall deliver to CMPI the resignation
            and release agreements provided for in Section 8.9.

ARTICLE IV

REPRESENTATIONS AND WARRANTIES OF CMPI

      CMPI represents and warrants to OCG that the statements contained in this
Article IV are true and correct except as disclosed in a disclosure letter, if
any, delivered by CMPI to OCG as of the date hereof:

4.1   Organization and Qualification

            (a) CMPI is a corporation duly organized, validly existing and in
      good standing under the laws of the State of California, is duly
qualified
      to do business as a foreign corporation and is in good standing in each

      jurisdiction in which the character of CMPI's properties or the nature of

      its business makes such qualification necessary, except in jurisdictions,
      if any, where the failure to be so qualified would not result in a CMPI
      Material Adverse Effect (as defined below). CMPI has all requisite
      corporate or other power and authority to own, use or lease its
properties
      and to carry on its business as it is now being conducted. CMPI has made
      available to OCG a complete and correct copy of its articles of

      incorporation and bylaws, each as amended to date, and CMPI's articles of
      incorporation and bylaws as so delivered are in full force and effect.
      CMPI is not in default in any respect in the performance, observation or
      fulfillment of any provision of its articles of incorporation or bylaws.

            (b) CMPI has no Subsidiaries (as defined below).

            (c) For purposes of this Agreement, (i) a "CMPI Material Adverse
      Effect" shall mean any event, circumstance, condition, development or
      occurrence causing, resulting in or having (or with the passage of time
      likely to cause, result in, or have) a material adverse effect on the
      financial condition, business, assets, properties, prospects or
results of

      operations of CMPI; and (ii) "Subsidiary" shall mean, with respect to any
      party, any corporation or other organization, whether incorporated or
      unincorporated, of which (x) at least a majority of the securities or

      other interests having by their terms voting power to elect a majority of
      the board of directors or others performing similar functions with
respect
      to such corporation or other organization is directly or indirectly
      beneficially owned or controlled by such party or by any one or more of
      its subsidiaries, or by such party and one or more of its
subsidiaries, or
      (y) such party or any Subsidiary of such party is a general partner of a
      partnership or a manager of a limited liability company.

4.2   Capitalization

      The authorized capital stock of CMPI consists of 3,000 shares of CMPI
Common Stock, of which 2,000 shares were issued and outstanding as of the date
of this Agreement and owned of record by the CMPI Shareholders. As of the date
of this Agreement, CMPI also has outstanding options or other rights entitling
the holders to acquire an aggregate of 138 shares of CMPI Common Stock, all of
which shares shall be issued and outstanding as of the Closing. As of the

Closing, there will be no outstanding subscriptions, options, rights, warrants,
convertible securities, stock appreciation rights, phantom equity or other
agreements or commitments obligating CMPI to issue, transfer, sell, redeem,

                                       7

repurchase or otherwise sell, issue or acquire any shares of CMPI Common Stock,
except for the CMPI Convertible Notes, which by their terms are convertible
into
shares of OCG Common Stock following the Closing.

4.3   Authority

      CMPI has full corporate power and authority to execute and deliver this
Agreement and to consummate the transactions contemplated hereby. The
execution,
delivery and performance of this Agreement and the consummation of the
transactions contemplated hereby have been duly and validly authorized by
CMPI's
board of directors and the CMPI Shareholders, and no other corporate
proceedings
on the part of CMPI are necessary to authorize this Agreement or to consummate
the transactions contemplated hereby. This Agreement has been duly and validly
executed and delivered by CMPI and, assuming the due authorization, execution
and delivery hereof and thereof by the other parties hereto, constitutes the
legal, valid and binding obligation of CMPI enforceable against CMPI in
accordance with its terms, except as such enforceability may be subject to the
effects of bankruptcy, insolvency, reorganization, moratorium and other laws
relating to or affecting the rights of creditors and of general principles of
equity (the "Enforceability Exception").

4.4   Consents and Approvals; No Violation

      The execution and delivery of this Agreement, the consummation of the

transactions contemplated hereby and the performance by CMPI of its obligations
hereunder will not:

            (a) conflict with any provision of CMPI's articles of incorporation
      or bylaws;

            (b) require any consent, waiver, approval, order, authorization or
      permit of, or registration, filing with or notification to, (i) any
      governmental or regulatory authority or agency (a "Governmental
      Authority"), except for applicable requirements of the Securities Act of
      1933, as amended (the "Securities Act"), state securities or blue sky
      laws, and approvals that are ministerial in nature and are customarily
      obtained from Governmental Authorities after the Effective Time in
      connection with transactions of CMPI of the same nature as are

      contemplated hereby ("Customary Post-Closing Consents") or (ii) any third
      party other than a Governmental Authority, other than such
      non-Governmental Authority third party consents, waivers, approvals,
      orders, authorizations and permits that would not (x) result in a CMPI
      Material Adverse Effect, (y) materially impair the ability of CMPI to
      perform its obligations under this Agreement or (z) prevent the
      consummation of any of the transactions contemplated by this Agreement;

            (c) result in any violation of or the breach of or constitute a

      default (with notice or lapse of time or both) under, or give rise to any

      right of termination, cancellation or acceleration or guaranteed payments
      or a loss of a material benefit under, any of the terms, conditions or
      provisions of any note, lease, mortgage, license, agreement or other
      instrument or obligation to which CMPI or any of its Subsidiaries is a
      party or by which CMPI or any of its Subsidiaries or any of their

      respective properties or assets may be bound, except for such violations,
      breaches, defaults, or rights of termination, cancellation or
      acceleration, or losses as to which requisite waivers or consents have
      been obtained or which, individually or in the aggregate, would not (i)
      result in a CMPI Material Adverse Effect, (ii) materially impair the
      ability of CMPI or any of its Subsidiaries to perform its obligations
      under this Agreement or (iii) prevent the consummation of any of the
      transactions contemplated by this Agreement;

            (d) violate the provisions of any order, writ, injunction,
judgment,
      decree, statute, rule or regulation applicable to CMPI or any of its
      Subsidiaries;

            (e) result in the creation of any lien, mortgage, pledge, security
      interest, encumbrance, claim or change of any kind ("Lien," if singular,
      or "Liens," if plural) upon any shares of capital stock or material
assets
      of CMPI or any of its Subsidiaries under any agreement or instrument to
      which CMPI or any of its Subsidiaries is a party or by which CMPI or any
      of its Subsidiaries or any of their materials assets is bound; or

            (f) result in any holder of any securities of CMPI being
entitled to
      appraisal, dissenters' or similar rights.

                                       8

4.5   Required Stockholder Vote or Consent

      The only vote of the holders of any class or series of capital stock of

CMPI that will be necessary to consummate the Merger and the other transactions
contemplated by this Agreement is the approval of this Agreement by the CMPI
Shareholders.

4.6   Financial Statements

      The unaudited consolidated financial statements of CMPI for the year
ended
December 31, 2004 (the "CMPI Financial Statements") delivered to OCG have been
prepared from, and are in accordance with, the books and records of CMPI and
fairly present the consolidated financial position of CMPI as of the date
thereof and the consolidated results of operations of CMPI for the periods
presented therein (subject to year-end adjustments).

4.7   Absence of Undisclosed Liabilities

      Since the date of the balance sheet included in the CMPI Financial
Statements, CMPI has incurred no Liabilities other than the CMPI Convertible
Notes, except in the ordinary course of business.

4.8   Absence of Certain Changes

      Except as contemplated by this Agreement, (a) CMPI has conducted its
business in all material respects in the ordinary course, (b) there has not
been
any change or development, or combination of changes or developments that,

individually or in the aggregate, would have a CMPI Material Adverse Effect and

(c) there has not been any amendment of any term of any outstanding security of
CMPI.

4.9   Taxes

      Except for matters that would not have a CMPI Material Adverse Effect,
CMPI has filed all material tax returns required by applicable law to be filed
by it and has paid or accrued all taxes shown as due thereon. CMPI has no
knowledge of a material tax deficiency which has been asserted or threatened
against CMPI.

4.10  Litigation

      Except for matters that would not have a CMPI Material Adverse Effect,
there is no suit, claim, action, proceeding or investigation pending or, to
CMPI's knowledge, threatened against or directly affecting CMPI or any of the
directors or officers of CMPI in their capacity as such. Neither CMPI nor, to
its knowledge, any officer, director or employee of CMPI, has been permanently
or temporarily enjoined by any order, judgment or decree of any court or any
other Governmental Authority from engaging in or continuing any conduct or

practice in connection with the business, assets or properties of CMPI, nor, to
the knowledge of CMPI, is CMPI or any officer, director or employee of CMPI
under investigation by any Governmental Authority. There is not in existence
any
order, judgment or decree of any court or other tribunal or other agency
enjoining or requiring CMPI to take any action of any kind with respect to its
business, assets or properties.

4.11  Compliance with Applicable Laws

      CMPI holds all material approvals, licenses, permits, registrations and
similar type authorizations necessary for the lawful conduct of its
business, as
now conducted, and, to CMPI's knowledge, such business is not being, and CMPI
has not received any notice from any Governmental Authority or person that any
such business has been or is being, conducted in violation of any law,
ordinance
or regulation, including without limitation any law, ordinance or regulation
relating to occupational health and safety, except for possible violations
which
either individually or in the aggregate have not resulted and would not result
in a CMPI Material Adverse Effect.

4.12  Insurance

      CMPI currently has in place all policies of insurance which are
reasonably
required in connection with the operation of the business of CMPI as currently
conducted in accordance with applicable laws and all agreements relating to
CMPI.

4.13  Permits

      Immediately prior to the Effective Time and except for Customary
Post-Closing Consents, CMPI will hold all of the permits, licenses,
certificates, consents, approvals, entitlements, plans, surveys, relocation

                                       9

plans, environmental impact reports and other authorizations of Governmental

Authorities ("Permits") required or necessary to own, operate, use and maintain
its properties and conduct its operations as presently conducted, except for
such Permits, the lack of which, individually or in the aggregate, would not
have a CMPI Material Adverse Effect.

4.14  Employee Benefit Plans

      Neither CMPI nor any trade or business, whether or not incorporated,
which
together with CMPI would be deemed a "single employee" within the meaning of
Section 414(b), (c) or (m) of the Code or Section 4001(b)(1) of the Employee
Retirement Income Security Act of 1974, as amended ("ERISA"), has, or on or
before the Closing will have, sponsored, maintained or contributed to any

employee benefits, plan or arrangement (including, but not limited to, any plan
described in Section 3(3) of ERISA) written six years prior to the Effective
Time.

4.15  Required Stockholder Vote or Consent

      The only vote of the holders of any class or series of capital stock of

CMPI that will be necessary to consummate the Merger and the other transactions
contemplated by this Agreement is the approval of this Agreement by the CMPI
Shareholders, which has been duly obtained as evidenced by their execution of
this Agreement.

4.16  Brokers

      No broker, finder or investment banker is entitled to any brokerage,
finder's fee or other fee or commission payable by CMPI in connection with the
transactions contemplated by this Agreement based upon arrangements made by or
on behalf of CMPI.

ARTICLE V

REPRESENTATIONS AND WARRANTIES OF OCG AND LEVINE

      OCG and Levine, jointly and severally, represent and warrant to CMPI as

follows, except as disclosed in a disclosure letter delivered by OCG to CMPI as
of the date hereof (the "OCG Disclosure Letter"):

5.1   Organization and Qualification

            (a) OCG is a corporation duly organized, validly existing and in
      good standing under the laws of the State of Delaware, is duly qualified
      to do business as a foreign corporation and is in good standing in each
      jurisdiction in which the character of OCG's properties or the nature of
      its business makes such qualification necessary. OCG has made
available to
      the Company a complete and correct copy of its certificate of
      incorporation and bylaws, each as amended to date, and OCG's certificate

      of incorporation and bylaws as so delivered are in full force and effect.
      OCG is not in default in any respect in the performance, observation or
      fulfillment of any provision of its certificate of incorporation or
      bylaws.

            (b) As of the consummation of the Spin-off and as of the Closing

      Date, OCG shall have no Subsidiaries other than Merger Sub, and shall own
      or hold no investment or other interest in any Person.

            (c) Merger Sub is a corporation duly organized, validly existing
and
      in good standing under the laws of the State of Delaware. OCG has made
      available to the Company a complete and correct copy of its
certificate of
      incorporation and bylaws, each as amended to date, and Merger Sub's

      certificate of incorporation and bylaws as so delivered are in full force
      and effect. Merger Sub is not in default in any respect in the
      performance, observation or fulfillment of any provision of its
      certificate of incorporation or bylaws.

            (d) Merger Sub is a direct, wholly-owned Subsidiary of OCG, was
      incorporated on September 9, 2004, and has not engaged in any business
      activities or conducted any operations of any kind, entered into any

      agreement or arrangement with any Person or entity, or incurred, directly
      or indirectly, any Liabilities, in each case, except in connection with
      its incorporation and the transactions contemplated hereby.

                                       10

5.2   Capitalization

      The authorized capital stock of OCG consists of ^common stock, $0.01 par
value per share (the "OCG Common Stock"), of which 50,000,000 shares are
authorized, and 1,000,000 shares of preferred stock, par value of $0.10 per
share ("OCG Preferred Stock" and, together with OCG Common Stock, the "OCG
Capital Stock"). Of the authorized shares of OCG Preferred Stock, 200,000
shares
have been designated as Series A Preferred Stock, 100,000 shares have been
designated as Series B Preferred Stock, 200,000 shares have been designated as
Series C Preferred Stock (the "OCG Series C Stock"), and 100,000 shares have
been designated as Series E Preferred Stock. As of the date of this Agreement,

OCG has issued and outstanding 49,901,121 shares of OCG Common Stock, no shares
of either A Preferred Stock or Series B Preferred Stock, 200,000 shares of OCG
Series C Stock, and 33,000 shares of Series E Preferred Stock. OCG also has
outstanding as of the date hereof OCG Stock Rights to acquire an aggregate of
18,841,262 shares of OCG Common Stock, which will be the subject of the
Exchange
Offer and which, to the extent the Exchange Officer is accepted by the holders
of such OCG Stock Rights, will no longer be outstanding as of the Closing.
Schedule 5.2 of the OCG Disclosure Letter sets forth a true and complete
list as

of the date hereof of all holders, and their holdings, of OCG Capital Stock and
OCG Stock Rights. The authorized capital stock of Merger Sub consists of 5,000
shares of Merger Sub Common Stock, all of which shares are outstanding and
owned, of record and beneficially, by OCG. There are no outstanding
subscriptions, options, rights, warrants, convertible securities, stock
appreciation rights, phantom equity or other agreements or commitments

obligating Merger Sub to issue, transfer, sell, redeem, repurchase or otherwise
sell, issue or acquire any shares of Merger Sub Common Stock. All outstanding
shares of OCG Capital Stock and Merger Sub Common Stock are validly issued,
fully paid and non-assessable, and free of preemptive rights. Except as set

forth above, and other than as contemplated in this Agreement, there are no OCG

Stock Rights, stock appreciation rights, phantom equity, or other agreements or
commitments obligating OCG or Merger Sub to issue, transfer, sell, redeem,
repurchase or otherwise acquire any shares of its respective capital stock of
any class.

5.3   Authority

            (a) Each of OCG and Merger Sub has full corporate power and
      authority to execute and deliver this Agreement and to consummate the

      transactions contemplated hereby. The execution, delivery and performance
      of this Agreement and the consummation of the transactions contemplated
      hereby have been duly and validly authorized by the respective board of
      directors of OCG and Merger Sub, and no other corporate proceedings on
the
      part of OCG and Merger Sub are necessary to authorize this Agreement
or to
      consummate the transactions contemplated hereby. This Agreement has been
      duly and validly executed and delivered by OCG and Merger Sub, and,
      assuming the due authorization, execution and delivery hereof by the
other
      parties hereto, constitutes the legal, valid, and binding obligations of
      OCG and Merger Sub enforceable against OCG or Merger Sub, as applicable,
      in accordance with its terms, except for the Enforceability Exception.

            (b) The Merger Shares have been duly and validly authorized for
      issuance pursuant to the Merger and, when issued at the Closing, will be
      validly issued, fully paid and non-assessable and free of any preemptive
      right. The Merger Stock Rights have been duly authorized for issuance
      pursuant to the Merger, and when issued at the Closing will be validly
      issued and free of any preemptive right.

5.4   Consents and Approvals; No Violation

      The execution and delivery of this Agreement, the consummation of the
transactions contemplated hereby and the performance by each of OCG and Merger
Sub of their respective obligations hereunder will not:

            (a) conflict with any provision of the respective certificate or
      articles of incorporation or bylaws of OCG or Merger Sub;

            (b) require any consent, waiver, approval, order, authorization or
      permit of, or registration, filing with or notification to, (i) any
      Governmental Authority, except for applicable requirements of the
      Securities Act, the Exchange Act, state securities or blue sky laws and

                                       11

      Customary Post-Closing Consents or (ii) any third party other than a
      Governmental Authority, other than such non-Governmental Authority third
      party consents, waivers, approvals, orders, authorizations and permits
      that would not (x) materially impair the ability of OCG or any of its
      Subsidiaries to perform its obligations under this Agreement or (y)
      prevent the consummation of any of the transactions contemplated by this
      Agreement;

            (c) result in any violation of or the breach of or constitute a

      default (with notice or lapse of time or both) under, or give rise to any

      right of termination, cancellation or acceleration or guaranteed payments
      or a loss of a material benefit under, any of the terms, conditions or
      provisions of any note, lease, mortgage, license, agreement or other
      instrument or obligation to which OCG or any of its Subsidiaries is a
      party or by which OCG or any of its Subsidiaries or any of their

      respective properties or assets may be bound, except for such violations,
      breaches, defaults, or rights of termination, cancellation or
      acceleration, or losses as to which requisite waivers or consents have
      been obtained or which, individually or in the aggregate, would not (i)
      materially impair the ability of OCG or any of its Subsidiaries to
perform
      its obligations under this Agreement or (ii) prevent the consummation of
      any of the transactions contemplated by this Agreement;

            (d) violate the provisions of any order, writ, injunction,
judgment,
      decree, statute, rule or regulation applicable to OCG or any of its
      Subsidiaries;

            (e) result in the creation of any Lien upon any properties or
assets
      or on any shares of capital stock of OCG or its Subsidiaries under any
      agreement or instrument to which OCG or any of its Subsidiaries is a
party
      or by which OCG or any of its Subsidiaries or any of their properties or
      assets is bound; or

            (f) result in any holder of any securities of OCG or any of its
      Subsidiaries being entitled to appraisal, dissenters' or similar rights.

5.5   OCG SEC Reports

      OCG filed with the Securities and Exchange Commission (the "SEC"), and
has
heretofore made available to CMPI, true and complete copies of each form,
registration statement, report, schedule, proxy or information statement and
other document (including exhibits and amendments thereto), including without
limitation any annual reports to stockholders incorporated by reference in
certain of such reports, required to be filed by it or its predecessors with
the
SEC since January 1, 2001 under the Securities Act or the Exchange Act
(collectively, the "OCG SEC Reports"). As of the respective dates such OCG SEC

Reports were filed or, if any such OCG SEC Reports were amended, as of the date
such amendment was filed, to OCG's and Levine's knowledge, each of the OCG SEC
Reports, including without limitation any financial statements or schedules
included therein, (a) complied in all material respects with all applicable
requirements of the Securities Act and the Exchange Act, as the case may be,
and
the applicable rules and regulations promulgated thereunder, and (b) did not
contain any untrue statement of a material fact or omit to state a material
fact
required to be stated therein or necessary in order to make the statements
therein, in light of the circumstances under which they were made, not
misleading.

5.6   Financial Statements

      To the best of their knowledge, each of the consolidated financial

statements of OCG contained in the OCG SEC Reports (including any related notes
and schedules) (the "OCG Financial Statements") has been prepared from, and is
in accordance with, the books and records of OCG and its consolidated
Subsidiaries, complies in all material respects with applicable accounting
requirements and with the published rules and regulations of the SEC with
respect thereto, has been prepared in accordance with generally accepted
accounting principles ("GAAP") applied on a consistent basis (except as may be
indicated in the notes thereto and subject, in the case of quarterly financial
statements, to normal and recurring year end adjustments) and fairly presents,
in conformity with GAAP applied on a consistent basis (except as may be

indicated in the notes thereto), the consolidated financial position of OCG and
its Subsidiaries as of the date thereof and the consolidated results of
operations and cash flows (and changes in financial position, if any) of OCG
and
its Subsidiaries for the periods presented therein (subject to normal year end

adjustments and the absence of financial footnotes in the case of any unaudited
interim financial statements).

                                       12

5.7   Absence of Undisclosed Liabilities

      Except as described in the most recent of the OCG SEC Reports, neither
OCG
nor any of its Subsidiaries has incurred any material liabilities or
obligations
of any nature (contingent or otherwise). As of the Closing Date, and after

giving effect to the Spin-off and the Exchange, OCG shall have no assets and no
Liabilities or other obligations other than its obligation to pay the dividend
of PSI shares as part of the Spin-off and other obligations under this
Agreement.

5.8   Absence of Certain Changes

      Except as disclosed in the OCG SEC Reports or as contemplated by this
Agreement, (a) since at least December 31, 2002, OCG has conducted no business
and has had no operations other than its ownership of PSI, (b) there has not
been any declaration, setting aside or payment of any dividend or other
distribution with respect to any shares of capital stock of OCG or any

repurchase, redemption or other acquisition by OCG of any outstanding shares of
capital stock or other securities of, or other ownership interests in, OCG or
its Subsidiaries and (c) there has not been any amendment of any term of any
outstanding security of OCG or its Subsidiaries.

5.9   Taxes

      OCG and each of its Subsidiaries have filed all material tax returns
required by applicable law to be filed by any of them and have paid or accrued
all taxes shown as due thereon. OCG and Levine have no knowledge of a material

tax deficiency, which has been asserted or threatened against OCG or any of its
Subsidiaries.

5.10  Litigation

      There is no suit, claim, action, proceeding or investigation pending or,
to OCG's and Levine's knowledge, threatened against or directly affecting OCG,
or any of the directors or officers of OCG in their capacity as such. Neither
OCG nor any officer, director or employee of OCG, has been permanently or

temporarily enjoined by any order, judgment or decree of any court or any other
Governmental Authority from engaging in or continuing any conduct or
practice in
connection with the business, assets or properties of OCG, nor, to the
knowledge
of OCG, is OCG, or any officer, director or employee of OCG or under
investigation by any Governmental Authority. There is not in existence any
order, judgment or decree of any court or other tribunal or other agency
enjoining or requiring OCG to take any action of any kind with respect to its
business, assets or properties.

5.11  Employee Benefit Plans

      Neither OCG nor any trade or business, whether or not incorporated, which
together with OCG would be deemed a "single employee" within the meaning of
Section 414(b), (c) or (m) of the Code or Section 4001(b)(1) of ERISA has,
or on
or before the Closing will have, sponsored, maintained or contributed to any

employee benefits, plan or arrangement (including, but not limited to, any plan
described in Section 3(3) of ERISA) written six years prior to the Effective
Time.

5.12  Compliance with Applicable Laws

      OCG holds all Permits, if any, necessary for the lawful conduct of its
businesses, as now conducted, and such businesses are not being, and OCG has
not
received any notice from any Governmental Authority or Person that any such
business has been or is being, conducted in violation of any law, ordinance or
regulation, including without limitation any law, ordinance or regulation
relating to occupational health and safety

5.13  Insurance

      OCG and its Subsidiaries currently have in place the policies of
insurance
described in Schedule 5.13 of the OCG Disclosure Letter.

5.14  Employees

      Schedule 5.14 of the OCG Disclosure letter sets forth a true and complete
list of all directors, officers and other employees of OCG.

5.15  Permits

                                       13

      Immediately prior to the Effective Time and except for Customary
Post-Closing Consents, OCG and its subsidiaries will hold all of the Permits
required or necessary to own, operate, use and maintain their respective
properties and conduct their respective operations as presently conducted.

5.16  Contracts

      As of the Closing Date, OCG will not be party to any material contract,
lease, indenture, agreement, arrangement or understanding other than this
Agreement and the other agreements provided for herein.

5.17  Required Stockholder Vote or Consent

      No vote or consent of the holders of any class or series of OCG Stock is
or will be necessary to consummate the Merger and the other transactions
contemplated by this Agreement.

5.18  Brokers

      Except for the finder's fee payable to Mercator Advisory Group
pursuant to
the letter of intent among OCG, CMPI and Rehearsals.com, Inc. relating to the
transactions contemplated by this Agreement, no broker, finder or investment
banker is entitled to any brokerage, finder's fee or other fee or commission
payable by OCG or any of its Subsidiaries or the Surviving corporations in
connection with the transactions contemplated by this Agreement based upon
arrangements made by or on behalf of OCG or any of its Subsidiaries.

5.19  Issuance of the Securities

      Upon the Effective Time, the OCG Series F Stock issuable pursuant to the
Merger will be duly authorized and validly issued, fully paid and
nonassessable,

free and clear of all Liens other than restrictions on transfer provided for or
referred to in this Agreement.

5.20  Sarbanes-Oxley; Internal Accounting Controls

      OCG is, or will be, in material compliance with all provisions of the
Sarbanes-Oxley Act of 2002 that are applicable to it as of the Closing Date.
OCG
and its Subsidiaries maintain a system of internal accounting controls
sufficient to provide reasonable assurance that (i) transactions are
executed in
accordance with management's general or specific authorizations, (ii)
transactions are recorded as necessary to permit preparation of financial
statements in conformity with GAAP and to maintain asset accountability, (iii)
access to assets is permitted only in accordance with management's general or
specific authorization, and (iv) the recorded accountability for assets is
compared with the existing assets at reasonable intervals and appropriate
action
is taken with respect to any differences. OCG's certifying officers have

evaluated the effectiveness of its controls and procedures as of the date prior
to the filing date of the most recently filed periodic report under the
Exchange
Act (such date, the "Evaluation Date"). OCG presented in its most recently
filed
periodic report under the Exchange Act the conclusions of the certifying
officers about the effectiveness of the disclosure controls and procedures
based
on their evaluations as of the Evaluation Date. Since the Evaluation Date,
there
have been no significant changes in OCG's internal controls (as such term is
defined in Item 307(b) of Regulation S-K under the Exchange Act) or, to OCG's
and Levine's knowledge, in other factors that could significantly affect OCG's
internal controls.

5.21  Registration Rights

      No person has any right to cause OCG to effect the registration under the
Securities Act of any securities of OCG or its Subsidiaries.

5.22  Exchange Act Requirements

      OCG's Common Stock is registered pursuant to Section 12(g) of the
Exchange
Act, and OCG has taken no action designed to, or which to its and Levine's
knowledge is likely to have the effect of, terminating the registration of OCG

Common Stock under the Exchange Act, nor has OCG received any notification that
the Commission is contemplating terminating such registration.

5.23  Transactions with Affiliates and Employees

      Except as set forth in the OCG SEC Reports, none of the officers or

directors of OCG and, to OCG's and Levine's knowledge, none of the employees of

OCG is presently a party to any transaction with OCG or any of its Subsidiaries

                                       14

(other than for services as employees, officers and directors), including any
contract, agreement or other arrangement providing for the furnishing of
services to or by, providing for rental of real or personal property to or
from,
or otherwise requiring payments to or from any officer, director or such
employee or, to OCG's and Levine's knowledge, any entity in which any officer,
director, or any such employee has a substantial interest or is an officer,
director, trustee or partner, in each case other than reimbursement for
expenses
incurred on behalf of OCG.

ARTICLE VI

REPRESENTATIONS AND WARRANTIES OF CMPI SHAREHOLDERS

      The CMPI Shareholders, severally and not jointly, each represents and
warrant, to OCG as follows:

6.1   Power and Authority Relative to this Transaction

      Such CMPI Shareholder has full power and authority and has taken all

action necessary to permit it to execute and deliver and to carry out the terms
of this Agreement and all other documents or instruments required hereby. This
Agreement constitutes the legal, valid and binding obligation of such CMPI
Shareholder, enforceable in accordance with its terms, except for the
Enforceability Exception.

6.2   Accredited Investor

      Such CMPI Shareholder is an "accredited investor" as that term is defined
in Rule 501 of Regulation D promulgated under the Securities Act.

6.3   Investment Representations

            (a) Such CMPI Shareholder is acquiring the OCG Series F Stock

      issuable pursuant to the Merger, and will acquire any Series F Conversion
      Shares, for such CMPI Shareholder's own account for the purpose of
      investment, and not with a view to distribution or resale thereof in

      violation of the Securities Act and the rules and regulations promulgated

      thereunder. Such CMPI Shareholder understands that none of the OCG Series
      F Stock or the Series F Conversion Shares has been registered under the
      Securities Act or any other applicable securities laws, and, therefore,
      cannot be resold unless they are subsequently registered under the
      Securities Act and other applicable securities laws, or unless an
      exemption from such registration is available. Such CMPI Shareholder
      agrees not to resell or otherwise dispose of all or any part of the OCG
      Series F Stock or the Series F Conversion Shares, except as permitted by
      law, including, without limitation, any regulations under the Securities
      Act and other applicable securities laws. Such CMPI Shareholder

      acknowledges that OCG does not have any present intention and is under no
      obligation to register the OCG Series F Stock or the Series F Conversion
      Shares under the Securities Act and other applicable securities laws.

            (b) Such CMPI Shareholder understands and agrees that all
      certificates evidencing any of the OCG Series F Stock or Series F
      Conversion Shares, whether upon initial issuance or upon any transfer
      thereof, shall bear a legend, prominently stamped or printed thereon,
      reading substantially as follows:

            "THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN

            REGISTERED UNDER THE SECURITIES ACT OF 1933 OR ANY OTHER SECURITIES
            LAWS. THESE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT
            WITH A VIEW TO DISTRIBUTION OR RESALE. SUCH SECURITIES MAY NOT BE
            OFFERED FOR SALE, SOLD, DELIVERED AFTER SALE, TRANSFERRED, PLEDGED
            OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION

            STATEMENT COVERING SUCH SECURITIES UNDER THE SECURITIES ACT OF 1933
            AND ANY OTHER APPLICABLE SECURITIES LAWS, UNLESS THE HOLDER SHALL
            HAVE OBTAINED AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE
            CORPORATION THAT SUCH REGISTRATION IS NOT REQUIRED OR THE
TRANSFEREE
            IS AN AFFILIATE OF THE HOLDER."

                                       15

6.4   Access to Information

      During the course of the transactions contemplated by this Agreement and
prior to the purchase of any OCG Series F Stock or Series F Conversion Shares,
such CMPI Shareholder has had the opportunity to ask questions of and receive
answers from representatives of OCG concerning the terms and conditions of the
offering of the OCG Series F Stock and the Series F Conversion Shares, and to

obtain additional information, documents, records and books relative to OCG and
an investment in OCG.

6.5   Knowledge and Experience

      Such CMPI Shareholder has sufficient knowledge and experience in business
and financial matters so as to enable such CMPI Shareholder to analyze and
evaluate the merits and risks of the investment contemplated hereby and is
capable of protecting its interest in connection with this transaction. Such
CMPI Shareholder is able to bear the economic risk of such investment,
including
a complete loss of the investment.

ARTICLE VII

CONDUCT OF BUSINESS PENDING THE MERGER

7.1   Conduct of Business by the OCG and CMPI Pending the Merger

      From the date hereof until the Effective Time, unless OCG and CMPI shall
otherwise agree in writing, and expect as otherwise contemplated by this
Agreement, OCG and CMPI and their respective Subsidiaries shall conduct their
business in the ordinary course consistent with past practice. Except as
otherwise provided in this Agreement, and without limiting the generality of
the
foregoing, from the date hereof until the Effective Time, without the written
consent of OCG and CMPI, which consent shall not be unreasonably withheld:

            (a) Neither OCG nor CMPI will adopt or propose any change to their
      respective certificate or articles of incorporation or bylaws;

            (b) Neither OCG nor CMPI will (i) declare, set aside or pay any
      dividend or other distribution with respect to any shares of capital
stock
      of the respective OCG and CMPI, or (ii) repurchase, redeem or otherwise
      acquire any outstanding shares of capital stock or other securities
of, or
      other ownership interests in, OCG or CMPI, as the case may be;

            (c) Neither OCG nor CMPI will, nor permit any of its Subsidiaries
      to, merge or consolidate with any other person or acquire assets of any
      other person except in the ordinary course of business or pursuant to
      transactions among wholly-owned subsidiaries of OCG or CMPI, as the case
      may be;

            (d) Neither OCG nor CMPI will, nor permit any of its Subsidiaries

      to, sell, lease, license or otherwise surrender, relinquish or dispose of
      any material assets or properties except in the ordinary course of
      business;

            (e) Neither OCG nor CMPI will (i) issue any securities (whether
      through the issuance or granting of options, warrants, rights or
      otherwise, (ii) enter into any amendment of any term of any outstanding
      security of such company or of any of its Subsidiaries, (iii) incur any
      indebtedness, except trade debt in the ordinary course of business and
      debt pursuant to existing or previously disclosed contemplated credit
      facilities or arrangements, (iv) increase in any material respect
      compensation, bonus or other benefits payable to, or modify or amend any
      employment agreements or severance agreements with, any executive
officer,
      or (v) enter into any settlement or consent with respect to any pending
      litigation, other than settlements in the ordinary course of business or
      on terms which are not otherwise materially adverse to such company and
      its Subsidiaries taken as a whole;

            (f) OCG and CMPI will not change any method of accounting or
      accounting practice by OCG and CMPI or any of their Subsidiaries, except
      for any such change required by GAAP;

            (g) Neither OCG nor CMPI will, nor permit any of its Subsidiaries
      to, (i) take, or agree or commit to take, any action that would make any

                                       16

      representation and warranty of the respective company hereunder
inaccurate
      in any material respect at, or as of any time prior to, the Effective
Time

      or (ii) omit, or agree or commit to omit, to take any action necessary or
      appropriate to prevent any such representation or warranty from being
      inaccurate in any material respect at any such time; and

            (h) Neither OCG nor CMPI will, nor permit any of its Subsidiaries
      to, agree or commit to do any of the foregoing.

ARTICLE VIII

ADDITIONAL AGREEMENTS

8.1   Amendment of Certificate of Incorporation

      As soon as is practicable following the Effective Time, OCG shall amend
its certificate of incorporation to increase the authorized shares of OCG
Common

Stock as necessary to permit the conversion, in full, of the OCG Series C Stock
and OCG Series F Stock and the issuance of the shares of OCG Common Stock
issuable upon conversion of OCG Series C Stock and OCG Series F Stock in
accordance with the terms thereof, and shall reserve out of such increased
authorized shares of OCG such number of shares equal at all times to the
aggregate shares of OCG Common Stock issuable upon such conversion.

8.2   Expenses

            (a) All Expenses (as defined below) incurred by the parties hereto
      shall be borne solely and entirely by the party that has incurred such
      Expenses.

            (b) "Expenses" as used in this Agreement shall include all
      out-of-pocket expenses (including, without limitation, all reasonable
fees
      and expenses of counsel, accountants, investment bankers, experts and
      consultants to a party hereto and its affiliates) incurred by a party or
      on its behalf in connection with or related to the authorization,

      preparation, negotiation, execution and performance of this Agreement and
      all other matters related to the consummation of the transactions
      contemplated hereby.

8.3   Cooperation

      Subject to compliance with applicable law, from the date hereof until the
Effective Time, each of the parties hereto shall confer on a regular and
frequent basis with one or more representatives of the other parties to report

operational matters of materiality and the general status of ongoing operations
and shall promptly provide the other parties or their counsel with copies of
all
filings made by such party with any Governmental Authority in connection with
this Agreement and the transactions contemplated hereby.

8.4   Publicity

      Neither the parties hereto nor any of their respective affiliates shall
issue or cause the publication of any press release or other announcement with
respect to the Merger, this Agreement or the other transactions contemplated
hereby without the prior consultation of the other parties, except as may be
required by law, and will use reasonable efforts to provide copies of such
release or other announcement to the other parties hereto, and give due
consideration to such comments as such other parties may have, prior to such
release.

8.5   Additional Actions

      Subject to the terms and conditions of this Agreement, each of the
parties
hereto agrees to use all reasonable efforts to take, or cause to be taken, all
action and to do, or cause to be done, all things necessary, proper or
advisable
under applicable laws and regulations, or to remove any injunctions or other
impediments or delays, to consummate and make effective the Merger and the
other
transactions contemplated by this Agreement.

8.6   Filings

      Each party hereto shall make all filings required to be made by such
party
in connection herewith or desirable to achieve the purposes contemplated
hereby,
and shall cooperate as needed with respect to any such filing by any other
party
hereto.

                                       17

8.7   Consents

      Each party hereto shall use all reasonable efforts to obtain all consents
necessary or advisable in connection with such party's obligations hereunder.

8.8   Notice of Certain Events

      Each party to this Agreement shall promptly as reasonably practicable
notify the other parties hereto of:

            (a) any notice or other communication from any Person alleging that
      the consent of such Person (or other Person) is or may be required in
      connection with the transactions contemplated by this Agreement;

            (b) any notice or other communication from any Governmental
      Authority in connection with the transactions contemplated by this
      Agreement; or

            (c) any actions, suits, claims, investigations or proceedings
      commenced or, to the best of such party's knowledge, threatened against,

      relating to or involving or otherwise affecting such party or any of such
      party's Subsidiaries which, if pending on the date of this Agreement,
      would have rendered untrue any representation contained in Article IV, V
      or VI, or which relate to the consummation of the transactions
      contemplated by this Agreement.

8.9   Resignations and Releases

      Prior to the Closing Date, OCG shall use its best efforts to obtain from

each of its directors, officers and employees a written resignation and release
agreement, substantially in the form attached hereto as Exhibit C, by which
each
such Person agrees to resign from OCG effective as of the Closing Date and to
release OCG and its affiliates from any and all Liability.

8.10  Spin-off and Exchange Offer

      Following the execution of this Agreement, OCG and PSI shall promptly
take
such steps as are necessary and appropriate to consummate the Spin-off, the
Exchange Offer and the other transactions contemplated hereby in compliance
with
all applicable laws, rules and regulations, including, without limitation, SEC
requirements.

8.11  Employee Covenants

            (a) Effective as of the Closing Date, PSI shall rehire on an
      "at-will" basis and at their then present rate of pay all employees of
OCG
      ("Employees"), including Employees who are absent from work due to
      disability or illness or who are on approved leave of absence or layoff
      status.

            (b) PSI shall assume at the Closing and be responsible for all
      obligations and Liabilities of OCG to Employees and any former employees
      or retirees of OCG, if any, including without limitation, those which
      arise under or pursuant to any Employee Benefit Plan. Without limiting
the

      foregoing or the generality of the assumption of the Liabilities pursuant
      to the Spin-off, PSI shall assume from and after the Closing and
      thereafter be responsible for:

                  (i) all Liabilities for holiday and vacation pay to which any
            Employee is entitled; and

                  (ii) all Liabilities under the worker's compensation laws of
            any jurisdiction with respect to Employees.

            (c) PSI shall be responsible for any and all severance benefits as
      may arise with respect to the termination of employment of any
Employee at
      any time, whether prior to, at or after the Closing Date.

                                       18

8.12  Related-Party Transactions

      During the one-year period following the Closing Date, OCG shall not sell
or issue, directly or indirectly, to any of the CMPI shareholders or any of
their respective affiliates any shares of OCG Capital Stock or any
securities or
other instruments convertible into or exchangeable for any such Capital Stock,
and shall not merge with or acquire, directly or indirectly, Rehearsals.com or
any other affiliate of OCG or of the Surviving Corporation, or any of their

respective affiliates, except, if at all, in a transaction in which the holders
of OCG Capital Stock immediately prior to the Effective Time receive shares of
OCG Capital Stock sufficient to prevent any dilution to such holders in their
respective percentage ownership of OCG Capital Stock as of the date of such
sale, issuance or other transaction.

ARTICLE IX

ESCROW

9.1   Escrow Generally

            (a) From and after the Closing, OCG shall hold in escrow the
      Retained Merger Shares until the same have been cancelled or released as
      provided in this Section 9.1.

            (b) For purposes of this Section 9.1, the following terms shall
have
      the meanings indicated:

                  (i) "Conversion Rate" shall mean the ratio that the Actual
            CMPI Note Conversion Shares bears to the Maximum CMPI Note
            Conversion Shares; and

                  (ii) "Escrow Release Date" means the date as of which all of
            the outstanding CMPI Convertible Notes shall have been
converted, in
            full, into shares of OCG Common Stock.

            (c) As of the Escrow Release Date, OCG shall cancel and retire a
      number of the Retained Merger Shares (the "Cancelled Retained Shares")
      determined by multiplying the Conversion Rate by the number of the
      Retained Merger Shares. Such cancellation and retirement shall be made
      ratably among the CMPI Shareholders in whose names such Retained Merger
      Shares are held.

            (d) Promptly following the Escrow Release Date, OCG shall prepare,
      execute and deliver to each CMPI Shareholder a stock certificate
      evidencing the net number of Retained Merger Shares, after deducting the

      Cancelled Retained Shares, to which such holder is entitled hereunder and
      after giving effect to the provisions of the CMPI Convertible Notes with
      respect to the relative percentage ownership of OCG by the "Existing
      Shareholders" (as defined in the CMPI Convertible Notes) and the holders
      of the CMPI Convertible Notes.

9.2   Transfer of Retained Shares and Stock Rights

      No CMPI Shareholder may sell, assign, transfer or otherwise dispose of
any
Retained Merger Shares, or any interest therein, other than by reason of the
laws of descent and distribution or succession by operation of law. Any
contemplated transfer in violation of this Section 9.2 shall be null and
void ab
initio.

ARTICLE X

CONDITIONS TO CONSUMMATION OF THE MERGER

10.1  Conditions to the Obligation of Each Party

      The respective obligations of each party to effect the Merger shall be
subject to the fulfillment at or prior to the Effective Time of the following
conditions:

            (a) no action, suit or proceeding instituted by any Governmental
      Authority shall be pending and no statute, rule or regulation and no

                                       19

      injunction, order, decree or judgment of any court or Governmental
      Authority of competent jurisdiction shall be in effect, in each case
which
      would prohibit, restrain, enjoin or restrict the consummation of the
      Mergers;

            (b) OCG and CMPI shall have obtained such permits, authorizations,
      consents, or approvals required to consummate the transactions
      contemplated hereby; and

            (c) the Spin-off and the Exchange Offer shall have been consummated
      as contemplated herein.

10.2  Conditions to the Obligations of OCG and Merger Sub

      The obligations of OCG and Merger Sub to effect the Merger are subject to

the satisfaction at or prior to the Effective Time of the following conditions:

            (a) CMPI shall have performed in all material respects its
      obligations under this Agreement required to be performed by it at or
      prior to the Effective Time, and the representations and warranties of

      CMPI contained in this Agreement, to the extent qualified with respect to
      materiality shall be true and correct in all respects, and to the extent
      not so qualified shall be true and correct in all material respects, in
      each case, as of the date of this Agreement and at and as of the
Effective
      Time as if made at and as of such time, and OCG shall have received a
      certificate of the Chief Executive Officer and the Chief Financial
Officer
      of CMPI as to the satisfaction of this condition;

            (b) all proceedings to be taken by CMPI in connection with the
      transactions contemplated by this Agreement and all documents,
instruments
      and certificates to be delivered by CMPI in connection with the
      transactions contemplated by this Agreement shall be reasonably
      satisfactory in form and substance to OCG and its counsel; and

            (c) from the date of this Agreement through the Effective Time,
      there shall not have occurred any change in the financial condition,
      business, operations or prospects of CMPI and its Subsidiaries, taken
as a
      whole, that would constitute a CMPI Material Adverse Effect.

10.3  Conditions to the Obligations of CMPI

      The obligation of CMPI to effect the Merger is subject to the
satisfaction
at or prior to the Effective Time of the following conditions:

            (a) OCG shall have performed in all material respects its
      obligations under this Agreement required to be performed by it at or

      prior to the Effective Time and the representations and warranties of OCG
      contained in this Agreement, to the extent qualified with respect to
      materiality shall be true and correct in all respects, and to the extent
      not so qualified shall be true and correct in all material respects, in

      each case as of the date of this Agreement and at and as of the Effective
      Time as if made at and as of such time, and CMPI shall have received a
      certificate of the Chief Executive Officer and the Chief Financial
Officer
      of OCG as to the satisfaction of this condition;

            (b) all OCG Stock Rights shall have been duly exchanged pursuant to
      the Exchange Offer;

            (c) the Series A Preferred Stock and Series B Preferred Stock of
OCG
      shall have been retired as provided in Section 3.4;

            (d) OCG shall have delivered to CMPI the signed statements referred

      to in Section 1.1(d) from the holders of all of the aggregate Liabilities
      of OCG other than holders of Liabilities which do not exceed as of the
      Closing $25,000 in the aggregate;

            (e) OCG shall have received the resignations and release agreements
      from each of its directors, officers and other employees as contemplated
      in Section 8.9; and

                                       20

            (f) all proceedings to be taken by OCG and Merger Sub, as the case
      may be, in connection with the transactions contemplated by this
Agreement
      and all documents, instruments and certificates to be delivered by OCG
and
      Merger Sub, as the case may be, in connection with the transactions
      contemplated by this Agreement shall be reasonably satisfactory in form
      and substance to CMPI and its counsel.

ARTICLE XI

SURVIVAL AND INDEMNIFICATION

11.1  Survival of Representations and Warranties

      The representations and warranties of the parties contained in this
Agreement shall survive the Effective Time for a period of two years following
the Effective Time.

11.2  Indemnification

            (a) From and after the Closing, PSI (as such, the "Indemnifying
      Party") shall indemnify, reimburse, defend and hold harmless OCG and the
      Surviving Corporation and OCG's other Subsidiaries and affiliates,
      successors or assigns (each, an "Indemnified Party") for any and all
      direct or indirect claims, losses, liabilities, damages (including
special
      and consequential damages), costs (including court costs) and expenses,
      including all reasonable attorneys' and accountants' fees and expenses
      (hereinafter a "Loss" or "Losses"), arising from or in connection with
(i)
      any breach or inaccuracy of any representation or warranty of OCG,
whether

      such breach or inaccuracy exists or is made on the date of this Agreement
      or as of the Closing, (ii) any breach of or noncompliance by OCG or
PSI of
      or with any covenant or agreement contained in this Agreement or in any

      other agreement or instrument delivered in connection herewith, (iii) any
      and all Liabilities of OCG or any of its Subsidiaries existing on or
prior
      to the Closing; and (iv) any attempt (whether or not successful) by any
      Person to cause or require any Indemnified Party to pay or discharge any
      Liability, or alleged Liability, of OCG or any of its Subsidiaries
      existing on or prior to the Closing. If, by reason of the claim of any
      Person relating to any of the matters subject to indemnification under
      this Section 11.2, an encumbrance, attachment, garnishment or
execution is
      placed upon any of the property or assets of any Indemnified Party, the

      Indemnifying Party shall also, promptly upon demand, furnish an indemnity
      bond satisfactory to the Indemnified Party to obtain the prompt
release of
      such encumbrance, attachment, garnishment or execution.

            (b) The Indemnifying Party shall be entitled to defend any claim,

      action, suit or proceeding made by any third party against an Indemnified
      Party with counsel approved by the Indemnified Party, such approval
not to
      be unreasonably withheld; provided, however, that the Indemnified Party
      shall be entitled to participate in such defense with counsel of its
      choice and at its own expense and, if the Indemnifying Party does not
      provide a competent and vigorous defense, then the Indemnified Party's
      participation shall be at the expense of the Indemnifying Party. The

      Indemnified Party shall provide such cooperation and access to its books,

      records and properties as the Indemnifying Party shall reasonably request
      with respect to such matter; and the parties shall cooperate with each
      other in order to ensure the proper and adequate defense thereof. An
      Indemnifying Party shall not settle any claim subject to indemnification
      hereunder without the prior written consent of the Indemnified Party,
      which consent shall not be unreasonably withheld or delayed.

            (c) With regard to claims of third parties for which
indemnification
      is payable hereunder, such indemnification shall be paid by the
      Indemnifying Party (or amounts may be set off by the Indemnified Party)
      upon the earliest to occur of: (i) the entry of a judgment against the
      Indemnified Party and the expiration of any applicable appeal period,
(ii)

      the entry of an unappealable judgment or final appellate decision against
      the Indemnified Party, (iii) the settlement of the claim, (iv) with
      respect to indemnities for tax liabilities, upon the issuance of any
final
      resolution by a taxation authority, or (v) with respect to claims before
      any administrative or regulatory authority, when the Loss is finally
      determined and not subject to further review or appeal; provided,
however,
      that the Indemnifying Party shall pay on the Indemnified Party's demand
      any cost or expense reasonably incurred by the Indemnified Party in
      defending or otherwise dealing with such claim.

                                       21

            (d) To seek indemnification hereunder, an Indemnified Party shall
      notify the Indemnifying Party of any claim for indemnification,
specifying

      in reasonable detail the nature of the Loss and the amount or an estimate
      of the amount thereof.

ARTICLE XII

TERMINATION, AMENDMENT AND WAIVER

12.1  Termination

      This Agreement may be terminated at any time prior to the Effective Time:

            (a) by the mutual written consent of OCG and CMPI;

            (b) by either OCG or CMPI if the Effective Time shall not have
      occurred on or before July 31, 2005 (the "Termination Date"); provided,
      that the party seeking to terminate this Agreement pursuant to this
      Section 12.1(b) shall not have breached in any material respect its
      obligations under this Agreement in any manner that shall have
proximately
      contributed to the failure to consummate the Mergers on or before the
      Termination Date;

            (c) by OCG or CMPI if there has been a material breach by one of
the
      other parties of any representation, warranty, covenant or agreement set
      forth in this Agreement which breach (if susceptible to cure) has not
been
      cured in all material respects within 20 business days following receipt
      by each party of notice of such breach; or

            (d) by OCG or CMPI if there shall be any applicable law, rule or
      regulation that makes consummation of the Merger illegal or if any
      judgment, injunction, order or decree of a court or other Governmental
      Authority of competent jurisdiction shall restrain or prohibit the
      consummation of the Merger, and such judgment, injunction, order or
decree
      shall become final and nonappealable.

12.2  Effect of Termination

            In the event of termination of the Agreement and the abandonment of
      the Merger pursuant to this Article XII, all obligations of the parties
      shall terminate, except the obligations of the parties pursuant to this
      Section 12.2 and except for the provisions of Sections 8.2 and 8.4;
      provided, however, that OCG shall remain obligated to CMPI under the New
      Promissory Note in accordance with the terms thereof, and nothing herein
      shall relieve any party from liability for any breach of this Agreement.

ARTICLE XIII

MISCELLANEOUS

13.1  Notices

      All notices or communications hereunder shall be in writing (including
facsimile or similar writing) addressed as follows:

To OCG or Merger Sub:                 Edward Levine
                                      President
                                      OCG Technologies, Inc.
                                      56 Harrison Street
                                      New Rochaelle, New York 10801
                                      Facsimile No: (914) 576-7821

with a copy to:                       Wynne B. Stern, Jr.
                                      6858 Treves Way
                                      Boyton Beach, Florida  33437
                                      Facsimile No: (561) 742-7878

                                       22

To CMPI:                              CenterStaging Musical Productions, Inc.
                                      3407 Winona Avenue
                                      Burbank, California 91504
                                      Facsimile No.:  (818) 848-4016

with a copy to:                       Troy & Gould Professional Corporation
                                      1801 Century Park East
                                      Los Angeles, California 90067
                                      Attention:  Alan B. Spatz
                                      Facsimile No:  (310) 201-4746

         Any such notice or communication shall be deemed given (i) when made,
if made by hand delivery, and upon confirmation of receipt, if made by

facsimile, (ii) one business day after being deposited with a next-day courier,
postage prepaid, or (iii) three business days after being sent certified or
registered mail, return receipt requested, postage prepaid, in each case
addressed as above (or to such other address as such party may designate in
writing from time to time).

13.2  Separability

      If any provision of this Agreement shall be declared to be invalid or
unenforceable, in whole or in part, such invalidity or unenforceability shall

not affect the remaining provisions hereof which shall remain in full force and
effect.

13.3  Assignment

      This Agreement shall be binding upon and inure to the benefit of the
parties hereto and their respective heirs, legal representatives, successors,
and assigns; provided, however, that neither this Agreement nor any rights
hereunder shall be assignable or otherwise subject to hypothecation and any
assignment in violation hereof shall be null and void.

13.4  Interpretation

      The headings contained in this Agreement are for reference purposes only
and shall not affect in any way the meaning or interpretation of this
Agreement.

13.5  Counterparts

      This Agreement may be executed in one or more counterparts, all of which

shall be considered one and the same Agreement, and shall become effective when
one or more such counterparts have been signed by each of the parties and
delivered to each party.

13.6  Entire Agreement

      This Agreement and the Ancillary Agreements represent the entire
agreement
of the parties with respect to the subject matter hereof and shall supersede
any
and all previous contracts, arrangements or understandings between the parties
hereto with respect to the subject matter hereof, including, without
limitation,
the letter of intent dated November 23, 2004.

13.7  Governing Law

      This Agreement shall be construed, interpreted, and governed in
accordance
with the laws of California, without reference to rules relating to
conflicts of
law.

13.8  Attorneys' Fees

      If any action at law or equity, including an action for declaratory

relief, is brought to enforce or interpret any provision of this Agreement, the
prevailing party shall be entitled to recover reasonable attorneys' fees and
expenses from the other party, which fees and expenses shall be in addition to
any other relief which may be awarded.

                                       23

13.9  No Third Party Beneficiaries

      Except as provided in Section 11.2, no person or entity other than the
parties hereto is an intended beneficiary of this Agreement or any portion
hereof.

13.10 Amendments and Supplements

      Prior to the Effective Time, this Agreement may be amended or
supplemented
in writing by OCG and CMPI with respect to any of the terms contained in this
Agreement, except as otherwise provided by law.

13.11 Extensions, Waivers, Etc.

      At any time prior to the Effective Time, either party may:

            (a) extend the time for the performance of any of the
obligations or
      acts of the other party;

            (b) waive any inaccuracies in the representations and warranties of
      the other party contained herein or in any document delivered pursuant
      hereto; or

            (c) waive compliance with any of the agreements or conditions of
the
      other party contained herein.

      Notwithstanding the foregoing, no failure or delay by any party hereto in
exercising any right hereunder shall operate as a waiver thereof nor shall any
single or partial exercise thereof preclude any other or further exercise

thereof or the exercise of any other right hereunder. Any agreement on the part
of a party hereto to any such extension or waiver shall be valid only if set
forth in an instrument in writing signed on behalf of such party.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

                                       24

         IN WITNESS WHEREOF, the parties hereto have duly executed this
Agreement as of the day and year first above written.

                                      OCG:

                                      OCG TECHNOLOGY, INC.

                                      By:
                                           -------------------------------
                                               Name:  Edward Levine
                                               Title:  President

                                      MERGER SUB:

                                      EPIDEMIC INTERVENTION SYSTEMS, INC.

                                      By:
                                           -------------------------------
                                               Name:  Edward Levine
                                               Title:  President

                                      CMPI:

                                      CENTERSTAGING MUSICAL PRODUCTIONS, INC.

                                      By:
                                           -------------------------------
                                               Name:
                                                       -------------------
                                               Title:
                                                       -------------------

                                      PSI:

                                      PRIMECARE SYSTEMS, INC.

                                      By:
                                           -------------------------------
                                               Name:  Edward Levin
                                               Title:  President

                                      LEVINE:

                                      ------------------------------------
                                      Edward Levine

                                       25

                                      CMPI SHAREHOLDERS:
                                      -----------------

                                      -------------------------------
                                      Roger Paglia

                                      -------------------------------
                                      Howard Livingston

                                      -------------------------------
                                      Jan Parent

                                      -------------------------------
                                      Johnny Caswell

                                       26

Schedule 4.2

List of CMPI Shareholders and Stock Rights Holders

Name                                                       Number of Shares of
----                                                        CMPI Common Stock
                                                            -----------------

Roger Paglia ..............................................
400

Howard Livingston .........................................
400

Jan Parent ................................................
600

Johnny Caswell ............................................
600

Others ....................................................
1381

-----

2,138

---------------------------------

(1)   All of such shares are issuable pursuant to outstanding rights in
favor of
      the holders and will be issued and outstanding as of the Closing.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00087-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00087-of-00352.parquet"}]]